PMID- 15287942
OWN - NLM
STAT- MEDLINE
DCOM- 20040920
LR  - 20111117
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 126
IP  - 4
DP  - 2004 Aug
TI  - In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment 
      is related to an increase of cytogenetically normal CD34 cells.
PG  - 501-7
AB  - The in vivo effect of recombinant human erythropoietin (rHuEpo) and granulocyte 
      colony-stimulating factor (G-CSF) combined treatment on CD34(+) cells was 
      evaluated by fluorescence in situ hybridization (FISH) in 13 myelodysplastic 
      syndrome (MDS) patients with known cytogenetic abnormalities. After treatment, 
      responsive patients presented a significantly lower proportion of FISH abnormal 
      CD34(+) cells than before treatment (P = 0.003), and in comparison with 
      unresponsive cases (P = 0.007). Response to treatment was associated with a 
      reduced degree of apoptosis in CD34(+) cells (P = 0.021): however, no difference 
      in telomere length was observed in responsive patients after growth factor 
      administration. Although the number of patients analysed was relatively small, 
      the present data suggest that, in MDS patients, response to rHuEpo and G-CSF may 
      be related to the proliferation of karyotypically normal but potentially 
      defective CD34(+) progenitor cells.
FAU - Rigolin, Gian Matteo
AU  - Rigolin GM
AD  - Section of Haematology, Department of Biomedical Sciences, University of Ferrara, 
      Ferrara, Italy. rglgmt@unife.it
FAU - Porta, Matteo Della
AU  - Porta MD
FAU - Ciccone, Maria
AU  - Ciccone M
FAU - Bugli, Anna Maria
AU  - Bugli AM
FAU - Bragotti, Letizia Zenone
AU  - Bragotti LZ
FAU - Mauro, Endri
AU  - Mauro E
FAU - Fraulini, Chiara
AU  - Fraulini C
FAU - Rossi, Antonella Russo
AU  - Rossi AR
FAU - Bardi, Antonella
AU  - Bardi A
FAU - Cuneo, Antonio
AU  - Cuneo A
FAU - Castoldi, Gianluigi
AU  - Castoldi G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antigens, CD34)
RN  - 0 (Recombinant Proteins)
RN  - 11096-26-7 (Erythropoietin)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD34/analysis
MH  - Apoptosis/drug effects
MH  - Bone Marrow Cells/pathology
MH  - Cell Division/drug effects
MH  - *Chromosome Aberrations
MH  - Drug Therapy, Combination
MH  - Erythropoietin/*therapeutic use
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Hematopoietic Stem Cells/*pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Myelodysplastic Syndromes/*drug therapy/genetics/pathology
MH  - Recombinant Proteins
MH  - Telomere/pathology
MH  - Treatment Outcome
EDAT- 2004/08/04 05:00
MHDA- 2004/09/21 05:00
CRDT- 2004/08/04 05:00
PHST- 2004/08/04 05:00 [pubmed]
PHST- 2004/09/21 05:00 [medline]
PHST- 2004/08/04 05:00 [entrez]
AID - BJH5086 [pii]
AID - 10.1111/j.1365-2141.2004.05086.x [doi]
PST - ppublish
SO  - Br J Haematol. 2004 Aug;126(4):501-7. doi: 10.1111/j.1365-2141.2004.05086.x.